Noncytolytic control of viral infections by the innate and adaptive immune response
- PMID: 11244031
- DOI: 10.1146/annurev.immunol.19.1.65
Noncytolytic control of viral infections by the innate and adaptive immune response
Abstract
This review describes the contribution of noncytolytic mechanisms to the control of viral infections with a particular emphasis on the role of cytokines in these processes. It has long been known that most cell types in the body respond to an incoming viral infection by rapidly secreting antiviral cytokines such as interferon alpha/beta (IFN-alpha/beta). After binding to specific receptors on the surface of infected cells, IFN-alpha/beta has the potential to trigger the activation of multiple noncytolytic intracellular antiviral pathways that can target many steps in the viral life cycle, thereby limiting the amplification and spread of the virus and attenuating the infection. Clearance of established viral infections, however, requires additional functions of the immune response. The accepted dogma is that complete clearance of intracellular viruses by the immune response depends on the destruction of infected cells by the effector cells of the innate and adaptive immune system [natural killer (NK) cells and cytotoxic T cells (CTLs)]. This notion, however, has been recently challenged by experimental evidence showing that much of the antiviral potential of these cells reflects their ability to produce antiviral cytokines such as IFN-gamma and tumor necrosis factor (TNF)-alpha at the site of the infection. Indeed, these cytokines can purge viruses from infected cells noncytopathically as long as the cell is able to activate antiviral mechanisms and the virus is sensitive to them. Importantly, the same cytokines also control viral infections indirectly, by modulating the induction, amplification, recruitment, and effector functions of the immune response and by upregulating antigen processing and display of viral epitopes at the surface of infected cells. In keeping with these concepts, it is not surprising that a number of viruses encode proteins that have the potential to inhibit the antiviral activity of cytokines.
Similar articles
-
Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).Clin Ter. 2006 Jul-Aug;157(4):377-86. Clin Ter. 2006. Retraction in: Clin Ter. 2008 May-Jun;159(3):207.. PMID: 17051976 Retracted. Review.
-
Natural killer cells in antiviral defense: function and regulation by innate cytokines.Annu Rev Immunol. 1999;17:189-220. doi: 10.1146/annurev.immunol.17.1.189. Annu Rev Immunol. 1999. PMID: 10358757 Review.
-
Non-cytotoxic antiviral activities of granzymes in the context of the immune antiviral state.Immunol Rev. 2010 May;235(1):128-46. doi: 10.1111/j.0105-2896.2010.00909.x. Immunol Rev. 2010. PMID: 20536560 Review.
-
Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections.Semin Immunol. 1998 Oct;10(5):383-90. doi: 10.1006/smim.1998.0138. Semin Immunol. 1998. PMID: 9799713 Review.
-
Induction and regulation of IFNs during viral infections.J Interferon Cytokine Res. 2004 Aug;24(8):439-54. doi: 10.1089/1079990041689665. J Interferon Cytokine Res. 2004. PMID: 15320958 Review.
Cited by
-
NKT cells promote Th1 immune bias to dengue virus that governs long-term protective antibody dynamics.J Clin Invest. 2024 Aug 1;134(18):e169251. doi: 10.1172/JCI169251. J Clin Invest. 2024. PMID: 39088280 Free PMC article.
-
Temporal Changes in Splenic Immune Cell Populations following Infection with a Very Virulent plus MDV in Commercial Meat-Type Chickens.Viruses. 2024 Jul 6;16(7):1092. doi: 10.3390/v16071092. Viruses. 2024. PMID: 39066253 Free PMC article.
-
Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination.Nat Immunol. 2024 Apr;25(4):633-643. doi: 10.1038/s41590-024-01787-z. Epub 2024 Mar 14. Nat Immunol. 2024. PMID: 38486021 Free PMC article.
-
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.Nat Commun. 2024 Jan 12;15(1):493. doi: 10.1038/s41467-023-43076-7. Nat Commun. 2024. PMID: 38216554 Free PMC article. Clinical Trial.
-
Adaptive immune cells are necessary for SARS-CoV-2-induced pathology.Sci Adv. 2024 Jan 5;10(1):eadg5461. doi: 10.1126/sciadv.adg5461. Epub 2024 Jan 3. Sci Adv. 2024. PMID: 38170764 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical